The company has secured an exclusive license to a dual antiviral prophylactic and therapeutic candidate, which is currently at a late-pre-clinical development stage. The immunotherapy candidate is able to target pan-respiratory virus infections, which could include influenza, respiratory syncytial virus (RSV), SARS-CoV-2 and others, according to In vivo data.
The candidate was developed at the University of Warwick follow 20 years of research from virologists professor Andrew Easton and professor Nigel Dimmock.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
